According to leading data and analytics company GlobalData, large pharma firms are eager to collaborate with biotech companies and academic labs to further the development of microbiome-targeted therapeutics in immunology,
Arbutus Biopharma Corporation and Roivant Sciences entered into an agreement to launch Genevant Sciences, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics.
Vaxart a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, completed the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine.
Recipharm, the contract development and manufacturing organisation (CDMO), has signed a licensing agreement with Altus Formulation to allow its customers to access new drug delivery technologies and products.
Novo Nordisk today announced the headline results from the first phase 3a trial with oral semaglutide. First ever diabetes pill can change whole diabetes market replacing injection for blood sugar control.
GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from its proprietary cannabinoid product platform, announced that The Lancet has published results from a Phase 3 study of Epidiolex